[go: up one dir, main page]

MX2009005358A - Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. - Google Patents

Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.

Info

Publication number
MX2009005358A
MX2009005358A MX2009005358A MX2009005358A MX2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A MX 2009005358 A MX2009005358 A MX 2009005358A
Authority
MX
Mexico
Prior art keywords
sulfanylmethyl
pyrazolo
pyrimidin
derivatives
cxcr2 antagonists
Prior art date
Application number
MX2009005358A
Other languages
English (en)
Inventor
Neil John Press
Simon James Watson
Carsten Spanka
David Porter
Peter Hunt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005358A publication Critical patent/MX2009005358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) y al uso de estos compuestos como farmacéuticos, por ejemplo para prevenir o tratar un padecimiento o enfermedad mediado por el receptor CXCR2.
MX2009005358A 2006-11-23 2007-11-21 Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. MX2009005358A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124682 2006-11-23
PCT/EP2007/062662 WO2008062026A1 (en) 2006-11-23 2007-11-21 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists

Publications (1)

Publication Number Publication Date
MX2009005358A true MX2009005358A (es) 2009-06-05

Family

ID=37891755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005358A MX2009005358A (es) 2006-11-23 2007-11-21 Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.

Country Status (10)

Country Link
US (1) US20100152205A1 (es)
EP (1) EP2094697A1 (es)
JP (1) JP2010510291A (es)
KR (1) KR20090082424A (es)
CN (1) CN101573359A (es)
AU (1) AU2007324472A1 (es)
BR (1) BRPI0718956A2 (es)
CA (1) CA2669579A1 (es)
MX (1) MX2009005358A (es)
WO (1) WO2008062026A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
US9278973B2 (en) 2012-10-25 2016-03-08 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
CN105980386B (zh) * 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
US10301378B2 (en) 2013-06-18 2019-05-28 New York University Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets
CN104086561A (zh) * 2014-07-08 2014-10-08 国家纳米科学中心 一种具有高填充因子的可溶性有机光伏小分子材料、制备方法及其用途
KR102411150B1 (ko) 2016-08-31 2022-06-21 아지오스 파마슈티컬스 아이엔씨. 세포 대사 과정의 억제제
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
KR20070011475A (ko) * 2004-05-12 2007-01-24 쉐링 코포레이션 Ｃｘｃｒ1 및 ｃｘｃｒ2 케모카인 길항제
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation

Also Published As

Publication number Publication date
US20100152205A1 (en) 2010-06-17
WO2008062026A1 (en) 2008-05-29
JP2010510291A (ja) 2010-04-02
KR20090082424A (ko) 2009-07-30
EP2094697A1 (en) 2009-09-02
CN101573359A (zh) 2009-11-04
AU2007324472A1 (en) 2008-05-29
CA2669579A1 (en) 2008-05-29
BRPI0718956A2 (pt) 2013-12-17

Similar Documents

Publication Publication Date Title
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
EA201070091A1 (ru) Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
CR9389A (es) Compuestos de imidazopiridazina
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
PL2164847T3 (pl) Związki 3-azabicyklo[3.3.0]oktanowe
MX2009006860A (es) Derivados de 2-aza-biciclo[3.1.0]hexano como antagonistas del receptor orexina.
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
WO2008008517A3 (en) Bridged diazepan orexin receptor antagonists
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2009009122A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal